HELIOWAVE TECHNOLOGIES LLC
College Station, TX · Medtech · Private
HelioSAFE system for rapid, automated, label-free sterility testing of biologics and medical countermeasures
- Grants
- $2.1M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $1.7M
- 1 award · Defense
- #239 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Defense · Phase I · HelioSAFE: a platform for the fast, label-free, automated evaluation of sterility | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · HelioQUANT: A Platform for Fast, Label-Free, Automated Evaluation of Bioburden | $233,475 | |
| Federal contract· 1 of 2 same day | Department of Defense · Phase II SBIR HELIOSAFE-2: A Platform For The Fast, Label-free, Automated Evaluation Of Sterility | $1,749,858 | |
| Federal grant· 2 of 2 same day | Department of Defense · Phase II · HelioSAFE-2: A Platform for the Fast, Label-Free, Automated Evaluation of Sterility | $1,500,000 | |
| Federal grant | Department of Agriculture · Foodborne Illnesses Caused By Pathogens Like E. Coli, Salmonella, And Listeria Pose A Significant Threat To Public Health, Safety, And The Economy. According To The Cdc, Approximately 48 Million People In The U.S. Experience Foodborne Illnesses Each Year, Equating To About 1 In 6 Americans, Resulting In Around 128,000 Hospitalizations And 3,000 Deaths Annually, Causing $20.5 Billion Of Financial Burden. Besides, Outbreaks Of These Illnesses Can Also Lead To Costly Recalls That Affect Farmers, Fo | $175,000 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 236 | Redbud Labs, Inc. | $1.8M | $520K |
| 237 | Particle Metrix | $1.8M | — |
| 238 | ROSELLINI SCIENTIFIC, LLC | $1.8M | — |
| 239 | HELIOWAVE TECHNOLOGIES LLC | $1.7M | — |
| 240 | Sofie Biosciences, Inc. | $1.7M | $9.7M |
| 241 | CytoViva Inc | $1.7M | $785K |
| 242 | DIAPEDIA, LLC | $1.7M | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.